ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, has successfully closed a $65 million Series A financing round. The funds will be used to advance its pipeline of multiple Phase 2 programs. ReproNovo, founded in 2021, is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. Their lead candidate, RPN-001 (leflutrozole), focuses on the development of an orally administered therapy for infertility in men with low serum testosterone. Another candidate, RPN-002 (nolasiban), is being developed to manage adenomyosis, an overgrowth of endometrial tissue into the uterus that can result in severe menstrual bleeding and pain, and to improve success rates in assisted reproductive technologies.